TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16358163
Drug: Patient-Controlled Sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Sedation (PCS) with midazolam: loading dose 0.028 mg/kg, bolus dose 1 mg, lock-out period 5 min, basal infusion rate 0.
Study: 16358163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 1 microg/kg of fentanyl (i.v.) and 0.028 mg/kg of midazolam (i.v.).
Study: 9564199
Drug: Adderall 5
Normalized name: Adderall 5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall 5 mg
Study: 9564199
Drug: Adderall 15
Normalized name: Adderall 15mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall 15 mg
Study: 9564199
Drug: Adderall 20
Normalized name: Adderall 20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall 20 mg
Study: 7815676
Drug: Long-chain triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain triglycerides (LCTs) infusion (0.07 g/kg.h‐1)
Study: 7815676
Drug: Medium-chain triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs) mixture infusion (50/50%, 0.07 g/kg.h‐1)
Study: 7815676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (glucose infusion only)
Study: 2651632
Drug: Cimetidine (30‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (30‐40 mg/kg/day)
Study: 19125855
Drug: Amlodipine/atorvastatin (5/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/atorvastatin (5/20 mg) plus therapeutic lifestyle changes (TLC)
Study: 11198157
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group with conventional analgesia (ketorolac I.V. 0.5 mg/kg/6 hours)
Study: 9176747
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 day 1, etoposide 130 mg/m2 days 1‐3
Study: 9176747
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, vinblastine 6 mg/m2, mitomycin 10 mg/m2 day 1
Study: 1548947
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisone and Vital HN (group III)
Study: 24902959
Drug: Community medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community medicine distributors (CMDs)
Study: 12470183
Drug: Rasagiline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 2 mg per day
Study: 17393324
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg bid)
Study: 11254118
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drug therapies (including DTIC plus interferon-alpha)
Study: 11254118
Drug: DTIC-containing multi-drug
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC-containing multi-drug regimens
Study: 11254118
Drug: Non-DTIC-containing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-DTIC-containing treatment programmes
Study: 9883438
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (paraffin-impregnated gauze, Jelonet)
Study: 2201224
Drug: Controlled-release dihydrocodeine
Normalized name: dihydrocodeine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release dihydrocodeine
Study: 2619027
Drug: Antiemetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiemetic therapy
Study: 28759396
Drug: 5-mL syringe
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mL syringe for 2-mL dose
Study: 28759396
Drug: 10-mL syringe
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mL syringe for 7.5-mL dose
Study: 19851159
Drug: USG guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG guided injection (triamcinolone 40 mg)
Study: 19851159
Drug: LMG guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMG guided injection (triamcinolone 40 mg)
Study: 19851159
Drug: USG guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG guided injection
Study: 19851159
Drug: LMG guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMG guided injection
Study: 16720966
Drug: Function-centred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Function-centred treatment (FCT) group with Functional Capacity Evaluation (FCE) results available to physicians.
Study: 16720966
Drug: Pain-centred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-centred treatment (PCT) group without FCE results available to physicians.
Study: 14707315
Drug: Ropinirole 0.25‐4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole 0.25‐4.0 mg once daily
Study: 11583826
Drug: ACE-inhibitors and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors and steroids
Study: 6360111
Drug: Orthokeratology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthokeratology treatment group
Study: 31668907
Drug: Manual Circumlaryngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Circumlaryngeal Therapy (MCT)
Study: 27082620
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) with 15 mL of 0.33% ropivacaine
Study: 16948810
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection before pneumatic dilatation
Study: 6828829
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment (1 Watt/cm2)
Study: 6828829
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment in lidocaine blocked fibromyotic muscle
Study: 6828829
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment in normal lidocaine pretreated muscle
Study: 31964381
Drug: Intrafractional vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrafractional vaginal dilation using a tampon of a specific diameter during treatment.
Study: 31964381
Drug: Standard (chemo)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (chemo) radiation with a total dose of 45-50.4 Gy to the pelvic and inguinal nodes with a boost to the anal canal up to 54-60 Gy.
Study: 31964381
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of a tampon during treatment.
Study: 28930830
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.3% ropivacaine plus 2 mL 1.0 μg/kg dexmedetomidine (group DR)
Study: 28930830
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.3% ropivacaine plus 2 mL normal saline (group R)
Study: 11006919
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of extra virgin olive oil per day
Study: 11006919
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of refined olive oil with no simple phenols
Study: 11006919
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of extra virgin olive oil (Postprandial trial)
Study: 2938520
Drug: Midazolam-alfentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-alfentanil combination
Study: 27020439
Drug: Uninterrupted use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted use of novel oral anticoagulants (NOACs) (group I, n = 64)
Study: 27020439
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of vitamin K antagonist (VKA) with INR between 2.0 and 3.0 (group III, n = 43)
Study: 27020439
Drug: VKA discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA discontinuation bridged with low molecular weight heparin (group IV, n = 43)
Study: 25190056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual care: STI testing, treatment, and counseling)
Study: 21036834
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B with 500 mL of physiologic saline and 30 mL (60 meq/L) of KCl
Study: 21036834
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B only (1 mg/kg/day for 20 days)
Study: 18834340
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 100 microg
Study: 18834340
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 200 microg
Study: 16086715
Drug: Budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 6 mg
Study: 11387857
Drug: Biofeedback‐assisted relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback‐assisted relaxation training (10 sessions of weekly training)
Study: 9702851
Drug: Eprosartan 300
Normalized name: eprosartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 300 mg twice a day for 7 days
Study: 9702851
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 7 days
Study: 2574906
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with H2-receptor antagonists
Study: 26003642
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (100 mL once a day for 7 days)
Study: 19298620
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in a proposed emergency treatment trial for SAH
Study: 16520413
Drug: Optimal postinfarction
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal postinfarction therapy (Control)
Study: 1630805
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment for chronic type B hepatitis
Study: 1630805
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment for chronic type C hepatitis
Study: 1630805
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment for hepatitis Delta infection
Study: 8096880
Drug: Fenoterol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 0.4 mg
Study: 6368141
Drug: Fenoterol 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 0.8 mg
Study: 23833852
Drug: Ropivacaine 0.165%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.165% with fentanyl 2.0 micro g/ml
Study: 23833852
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% with fentanyl 2.0 micro g/ml
Study: 21092287
Drug: PEG‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alpha‐2b (40‐kDa), single 180 micrograms dose, subcutaneously administered
Study: 21092287
Drug: PEG‐IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alpha‐2a (reference), single 180 micrograms dose, subcutaneously administered
Study: 21487851
Drug: Celsior solution
Normalized name: Fraxinus excelsior leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior solution (CS)
Study: 10640263
Drug: pivampicillin plus
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivampicillin plus pivmecillinam (40 mg/kg/day and 50 mg/kg/day respectively)
Study: 10640263
Drug: pivampicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivampicillin (50 mg/kg/day)
Study: 3932049
Drug: Misoprostol 100
Normalized name: MISOPROSTOL 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 100 micrograms administered q.i.d. for up to four weeks
Study: 29660425
Drug: Certolizumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab 400 mg every 2 weeks for 16 weeks
Study: 29660425
Drug: Certolizumab 200
Normalized name: certolizumab 200 mg subcutaneous kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab 200 mg every 2 weeks for 16 weeks
Study: 21846661
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS) with brief repeated behavioral intervention (BRBI)
Study: 21846661
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch with brief repeated behavioral intervention (BRBI)
Study: 20671013
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (≥500 mg/day)
Study: 18209721
Drug: DNAemia cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNAemia cutoff of 10,000 copies per ml whole blood
Study: 18209721
Drug: Antigenemia positivity
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigenemia positivity for initiation of preemptive therapy
Study: 12556541
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (multifactorial intervention targeting hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention with aspirin)
Study: 10644551
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion at 6 mg x kg(‐1) x min(‐1)
Study: 10644551
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion at 2 mg x kg(‐1) x min(‐1)
Study: 10644551
Drug: Glucose pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose pulse induction (6 mg x kg(‐1) x min(‐1))
Study: 1653671
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (320 fmol/min)
Study: 11521984
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bid for 4 weeks
Study: 6301262
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bid for up to 8 weeks (after initial 4 weeks of placebo for unhealed patients)
Study: 27480499
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) posterior surface area estimates
Study: 25370155
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment for 4 weeks
Study: 23288881
Drug: Ezetimibe/simvastatin (EZ/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin (EZ/S) 10/20 mg
Study: 23288881
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg)
Study: 23288881
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to rosuvastatin 10 mg
Study: 14996137
Drug: Lamotrigine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (long-term treatment)
Study: 14996137
Drug: Risperidone (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (short-term treatment)
Study: 14996137
Drug: Divalproex (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (short-term treatment)
Study: 14996137
Drug: Fluoxetine (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (short-term treatment)
Study: 14996137
Drug: Venlafaxine (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (short-term treatment)
Study: 14996137
Drug: Lithium (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (long-term treatment)
Study: 12575569
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) plus bronchial arterial infusion chemotherapy (BAIC)
Study: 12575569
Drug: Bronchial arterial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial arterial infusion chemotherapy (BAIC) alone
Study: 3243913
Drug: Single 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 16 mg dose
Study: 3243913
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg dose given hourly for 10 doses
Study: 3243913
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 4.8 mg, followed by 1.6 mg doses given every hour for seven additional doses
Study: 3243913
Drug: Dosing regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing regimen 1
Study: 3243913
Drug: Dosing regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing regimen 2
Study: 3243913
Drug: Dosing regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing regimen 3
Study: 30626409
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular scopolamine augmentation
Study: 30626409
Drug: Low-dose intramuscular
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intramuscular scopolamine augmentation
Study: 25796459
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg, 16 cycles, IV every 3 weeks)
Study: 16964670
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (Engerix‐B SKB 20 microg) administered according to a 0, 1, 2 month regime.
Study: 11111813
Drug: Biseko (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biseko (standardized serum protein solution)
Study: 8329259
Drug: propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 2.5 mg kg‐1
Study: 8329259
Drug: thiopentone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiopentone 5.0 mg kg‐1
Study: 10642369
Drug: Creatine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (5 g Cr monohydrate + 20 g glucose) four times per day for 5 days
Study: 8697183
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL bolus of any solution
Study: 7971477
Drug: Tris (pH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tris (pH = 10.5) intravenous infusion followed by hyperventilation
Study: 3653415
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg bid for 7 days
Study: 3653415
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg bid for 7 days
Study: 3653415
Drug: Epostane 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epostane 200 mg qid for 7 days
Study: 23953888
Drug: Isotretinoin-Lidose formulation
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin-Lidose formulation
Study: 23953888
Drug: Innovator isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator isotretinoin formulation
Study: 21156983
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 15 mL each of bupivacaine 0.5% and mepivacaine 1.5%
Study: 10638351
Drug: EEG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG biofeedback treatment
Study: 10768305
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) in dosages of 100‐1,600 mg/day
Study: 749854
Drug: Carbenoxolone plus
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone plus antacids (CBX + AA)
Study: 31279962
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CTX) 50 mg daily (Arm A)
Study: 31279962
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CTX) 50 mg daily with celecoxib 400 mg twice daily (Arm B)